Bevacizumab: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
* Major Indication: Colorectal [[Cancer]]<br /> | * Major Indication: Colorectal [[Cancer]]<br /> | ||
* Drug Class: [[Vascular Endothelial Growth Factor]] Inhibitor - [[Monoclonal Antibody]] | * Drug Class: [[Vascular Endothelial Growth Factor]] Inhibitor - [[Monoclonal Antibody]] | ||
* Date of FDA Approval (Patent Expiration): 2004 ( | * Date of FDA Approval (Patent Expiration): 2004 (2019) | ||
* 2009 Sales: $4.8 Billion | * 2009 Sales: $4.8 Billion | ||
* Importance: It is one of the best selling [[cancer]] treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months. | * Importance: It is one of the best selling [[cancer]] treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months. | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||